Based in Laupheim, Germany, Rentschler Biopharma prides itself on the contribution it makes to the global availability of biopharmaceuticals as a full-service CDMO and outsourcing partner for bioprocess development and current good manufacturing practice (cGMP).

Federico Pollano, Rentschler's senior vice president for business development, spoke with ScienceBoard.net at the 2022 Biotechnology Innovation Organization (BIO) International Convention about how the company is navigating the worldwide supply chain disruption.

Pollano said that over the last two years Rentschler has "strategically" sourced raw materials and media, while "working on different systems" including both disposable and stainless steel bioreactors. He noted that Rentschler pioneered single-use manufacturing and was among the first adopters of disposable bioreactors in the CDMO business.

However, Rentschler offers both disposable and stainless steel equipment. The company has stainless steel bioreactors up to 3,000L as well as 2,000L and 1,000L single-use bioreactors.

"You can balance [the options] also in stainless steel where you have less material demand," Pollano said. "It's very important to be flexible and also to be able to adapt your processes according to the available media, and on the other side also to have access to the inventories from the relevant vendors."

Watch the video below to learn more.

NIH seeks industry partners for technology transfer
The National Institutes of Health (NIH) is the world’s largest public funder of biomedical research. ScienceBoard.net spoke with Michael Salgaller...

A case study on partnering between patient advocacy organizations and biotech
Last week's 2022 Biotechnology Innovation Organization (BIO) International Convention in San Diego gave patient advocacy organizations and biotech companies...

Estonia’s ambitious plans to grow its biotech industry
The Baltic state of Estonia's biotech industry is expected to grow tenfold this decade and offers significant opportunities for Estonian companies. ScienceBoard.net...

Using the power of plants to develop novel biopharmaceuticals
Biologics manufacturing company iBio is using plants as bioreactors to develop and manufacture therapeutics and vaccines. ScienceBoard.net spoke...

Fauna Bio leverages animal genomics, hibernation biology to target human diseases
Biotech company Fauna Bio is leveraging animal genomics and hibernation biology to develop novel translational therapeutics for disease prevention and...

Overcoming the challenges of off-the-shelf allogeneic cell therapies
Chimeric antigen receptor T-cell therapy has emerged as one of the major breakthroughs in cancer immunotherapy in the last decade. In a video interview...

Apeiron Biologics' spinout invIOs targets solid tumors with novel cell therapy platform
Apeiron Biologics' spinout invIOs has a proprietary cell therapy platform for the modulation of intracellular immuno-oncology targets that enables rapid...

Struggle to include women in clinical trials continues despite gains
Though female participation in clinical trials has been steadily improving over the years, most of the women enrolled in trials are white and not members...

Patient advocacy organizations look to partner with pharma companies
Patient advocacy organizations are looking to partner with pharmaceutical companies, offering resources and expertise to maximize the impact and efficiency...

How to develop a sustainable portfolio for cell, gene therapy platforms
Michael Retterath, a Biotechnology Innovation Organization International Convention 2022 panelist and chief business officer at Spark Therapeutics, spoke...

Biotech industry execs, not scientists, remain male-dominated
A panel at the 2022 Biotechnology Innovation Organization International Convention will explore how to close the gender gap in the biotech industry and...

The ‘voice of the patient’ needs to be heard in clinical trials: study
Patient recruitment and retention are among the biggest challenges facing clinical research, particularly in studies targeting rare diseases that have...

New era of nonviral DNA-delivered gene therapy seen emerging
Advancements in nucleic acid-encoded therapeutics over the past decade have sparked the emergence of a new era in nonviral DNA-delivered gene therapy,...

Biotech innovator recounts decades-long journey to create drug discovery technology
Dr. Stan Crooke, PhD, founder, chairman, and chief executive officer of RNA therapy company Ionis Pharmaceuticals, pioneered development of the antisense...

Biotech industry to gather at BIO International Convention in San Diego
More than 11,000 attendees from around the globe will be in San Diego, June 13-16, for the 2022 Biotechnology Innovation Organization (BIO) International...